Testing the additional predictive value of high-dimensional molecular data by Boulesteix, Anne-Laure & Hothorn, Torsten
Anne-Laure Boulesteix and Torsten Hothorn
Testing the additional predictive value
of high-dimensional molecular data
Technical Report Number 064, 2009
Department of Statistics
University of Munich
http://www.stat.uni-muenchen.de
Testing the additional predictive value of
high-dimensional molecular data
Anne-Laure Boulesteix1,2 and Torsten Hothorn2
September 1, 2009
1 Department of Medical Informatics, Biometry and Epidemiology, University of
Munich, Marchioninistr. 15, D-81377 Munich, Germany
2 Department of Statistics, University of Munich, Ludwigstr. 33, D-80539 Munich,
Germany
Abstract
While high-dimensional molecular data such as microarray gene expression
data have been used for disease outcome prediction or diagnosis purposes for
about ten years in biomedical research, the question of the additional predictive
value of such data given that classical predictors are already available has long
been under-considered in the bioinformatics literature.
We suggest an intuitive permutation-based testing procedure for assessing
the additional predictive value of high-dimensional molecular data. Our method
combines two well-known statistical tools: logistic regression and boosting re-
gression. We give clear advice for the choice of the only method parameter (the
number of boosting iterations). In simulations, our novel approach is found to
have very good power in different settings, e.g. few strong predictors or many
weak predictors. For illustrative purpose, it is applied to the two publicly avail-
able cancer data sets. Our simple and computationally efficient approach can be
used to globally assess the additional predictive power of a large number of can-
didate predictors given that a few clinical covariates or a known prognostic index
are already available.
1
1 Background
While high-dimensional molecular data such as microarray gene expression data have
been used for disease outcome prediction or diagnosis purposes for about ten years
[1] in biomedical research, the question of the additional predictive value of such data
given that classical predictors are already available has long been under-considered in
the bioinformatics literature.
This issue can be summarized as follows. For a given prediction problem (for ex-
ample tumor subtype diagnosis or long-term outcome prediction), we consider two
types of predictors. On the one hand, conventional clinical covariates such as, e.g. age,
sex, disease duration or TNM scores are available as potential predictors. They have of-
ten been extensively investigated and validated in previous studies. On the other hand,
we have molecular predictors which are generally much more difficult to measure and
collect than conventional clinical predictors, and not yet well-established. In the con-
text of translational biomedical research, investigators are interested in the additional
predictive value of such predictors over classical clinical covariates.
A particular challenge from the statistical point of view is that these molecular pre-
dictors are often high-dimensional, which potentially leads to overfitting problems and
overoptimistic conclusions on their additional predictive power [2, 3]. The question
whether high-dimensional molecular data like microarray gene expression have addi-
tional predictive power compared to clinical variables can thus not be answered using
standard statistical tools such as logistic regression (for class prediction) or the pro-
portional hazard model (for survival analysis). Hence, there is a demand for alternative
approaches.
The formulation ”additional predictive value compared to classical clinical predic-
tors” is ambiguous because it actually encompasses two distinct scenarii. In the first
scenario, the prediction model based on clinical covariates is given (for instance from a
previous publication) and can be directly applied to the considered data set. Such mod-
els are usually denoted as ”risk score” or ”index” in the medical literature and often
use a very small number of predictors, such that they are widely applicable in further
studies. However, clinicians often want to develop their own clinical score using their
own data (second scenario) because it is expected to yield higher accuracy for their
particular patient collective, or because they want to predict a different outcome or use
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different predictors. These two scenarii are different from the statistical point of view:
in the first scenario the prediction rule based on clinical covariates is fixed, while it has
to be constructed from the data in the second scenario.
In this article, we present a method for testing the additional predictive value of
high-dimensional data that fulfills the following requirements:
• Requirement 1: The additional predictive value is assessed within a hypothe-
sis testing framework where the null hypothesis corresponds to ”no additional
predictive value”.
• Requirement 2: The focus is on the additional predictive value, i.e. the model
selection procedure for the high-dimensional data takes the clinical covariates
into account.
• Requirement 3: The method can address the two scenarii described above (fixed
risk score or clinical prediction model estimated from the data).
In the last few years, a couple of methods fulfilling one of these requirements
have been proposed to handle this problem. In the context of class prediction, the pre-
validation procedure proposed by Efron and Tibshirani [4, 5] consists of constructing
a prediction rule based on the high-dimensional molecular data only within a cross-
validation framework. The cross-validated predicted probabilities are then considered
as a new pseudo-predictor. The question of the additional predictive value is answered
by classical hypothesis testing within a logistic regression model involving both the
clinical covariates and the cross-validated predicted probabilities. However, this ap-
proach may yield a substantial bias because, roughly speaking, the cross-validated
probabilities are not independent from each other. This bias is quantitatively assessed
in the subsequent publication [5]. The authors suggest a (computationally intensive)
permutation-based testing scheme to circumvent this problem. Another pitfall of the
pre-validation procedure is that the cross-validated probabilities are constructed with-
out taking the clinical covariates into account. Hence, pre-validation does not fulfill
requirement 2. For example, if the high-dimensional molecular predictors are highly
correlated with the clinical predictors, so will be the cross-validated predicted probabil-
ities. Constructing the cross-validated predicted probabilities in such a way that they
are complementary to rather than redundant with the clinical covariates potentially
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yields different results [6]. On one hand, pre-validation as originally suggested [4]
may overestimate the additional predictive value because the predictive value of clini-
cal covariates is ”shared” by the clinical covariates themselves and the cross-validated
predicted probabilities in the logistic regression model, due to correlation. On the other
hand, it may be underestimated because subtle contributions of the high-dimensional
molecular data to the prediction problem are likely to be overcome by more obvious
contributions- which are redundant with the contributions of the clinical covariates.
Another important method for assessing high-dimensional predictors while adjust-
ing for clinical covariates is Goeman’s global test [7]. In the generalized linear model
framework, it is assumed that the regression coefficients of the molecular variables are
sampled from some common distribution with expectation zero and variance τ 2. The
null-hypothesis that all regression coefficients are zero can then be reformulated as
τ 2 = 0. In their second paper on this subject, the same authors suggest a variant of
this test that adjusts for additional (e.g. clinical) covariates in the context of survival
analysis [8]. This adjustment methodology can also be applied to the case of class
prediction and is implemented in the function globaltest from the Bioconductor
package globaltest [9] through the adjust option. In the present paper, we address
this question using a completely different methodology based on permutation testing
and boosting regression.
Other authors address the issue of the additional predictive value in the con-
text of prediction and derive combined prediction rules using both clinical predictors
and high-dimensional molecular data. A method proposed recently embeds the pre-
validation procedure described above into PLS dimension reduction and then uses both
clinical covariates and pre-validated PLS components as predictors in a random forest
[10]. This method has the same inconvenience as the original pre-validation approach,
in the sense that the PLS components are built without taking the clinical covariates
into account. They may thus be redundant with clinical predictors and do not focus
particularly on the residual variability, as outlined above for the original pre-validation
procedure. Hence, this method does not fulfill requirement 2. This pitfall is shared by
many recent machine learning approaches for constructing combined classifiers using
both clinical and high-dimensional molecular data [11, 12].
In contrast, the CoxBoost approach [6] for survival analysis with mandatory co-
variates takes clinical covariates into account while selecting the model for the high-
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dimensional predictors. Clinical covariates are forced into the model through a cus-
tomized penalty matrix. The authors suggest to set this penalty matrix to a diagonal
matrix with entries 1 and 0 for ”penalization” and ”no penalization”, respectively. This
approach has the major advantages that it can i) take into account the clinical covari-
ates while updating the coefficients of the molecular variables, ii) easily handle the
n p, and iii) yield a sparse molecular signature without additional preliminary vari-
able selection procedure. The CoxBoost approach is presented as survival prediction
method. However, a similar procedure can be used in the context of class prediction
[13]. This approach fulfills requirements 2 but not requirement 1 since its aim is to
provide a combined prediction model rather than a testing procedure.
Motivated by the strong advantages of the CoxBoost approach, we suggest an al-
ternative simple two-stage approach which also uses a boosting algorithm, but in a
different scheme which is more appropriate for the testing purposes considered here.
Our approach combines a standard generalized linear model for modeling the clinical
covariates (step 1) with a boosting algorithm for modeling the additional predictive
value of high-dimensional molecular data (step 2). The differences between our ap-
proach and the CoxBoost approach [6] are as follows. In contrast to the CoxBoost
method, we first fit a classical generalized linear model to the clinical covariates (first
step) and then focus on the molecular variables (second step) without changing the
coefficients fitted in the first step. This makes our procedure potentially easier to in-
terpret, since most clinicians are familiar with standard logistic regression or Cox re-
gression which are used in the first step but might be confused by the iterative update
of the coefficients. Moreover, by fixing the coefficients of the clinical covariates in the
first step, we set the focus on additional predictive value more clearly than if these
coefficients are allowed to change depending on the effect of the molecular variables.
Moreover, we follow the well-established boosting algorithm described in [14] in each
the update g[m] (see Methods Section for an explanation of the notation) is multiplied
by a small shrinkage factor ν. Instead, CoxBoost does not multiply through ν but pe-
nalizes the update through a penalty matrix in the loss function. Like the CoxBoost
approach, our method fulfills requirement 2. To address requirement 1, we suggest a
simple permutation-based testing procedure. The resulting novel approach thus fulfills
the two first requirements. Moreover, we suggest a variant for addressing the applica-
tion of a risk score fitted previously using other data (requirement 3).
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In the next section, we briefly review the methods involved in the first step (logistic
regression) and second step (boosting with componentwise linear least squares), and
we describe the combined two-step procedure as well as the permutation test.
2 Methods
In the following, we consider a random vector of clinical covariates (Z1, . . . , Zq)′ with
n independent realizations zi = (zi1, . . . , ziq)′, for i = 1, . . . , n. Similarly, the random
vector of molecular covariates is denoted as (X1, . . . , Xp)′ (with p > n) with n real-
izations xi = (xi1, . . . , xip)′, for i = 1, . . . , n. The response variable is denoted as Y
and coded as Y ∈ {−1, 1}, with realizations y1, . . . , yn.
2.1 Logistic regression
Logistic regression is the standard statistical tool for constructing linear class predic-
tion rules and assessing the significance of each predictor. It is implemented in all sta-
tistical software tools, for instance in R within the generic function glm. The logistic
regression model is given as
log
P (Y = 1|Z1, . . . , Zq)
P (Y = −1|Z1, . . . , Zq) = β0 + β1Z1 + · · ·+ βpZq,
where Y is the binary response variable of interest and Z1, . . . , Zq denote the q predic-
tors. In the two-stage approach suggested in this article, Z1, . . . , Zq correspond to the
clinical predictors. The maximum-likelihood estimates βˆ0, . . . , βˆq of the model coeffi-
cients β0, . . . , βq can be obtained via iterative algorithms such as the Newton-Raphson
procedure. For each new observation znew = (znew,1, . . . , znew,q)′, one obtains the
so-called linear predictor as
ηˆnew = βˆ0 + βˆ1znew,1 + · · ·+ βˆpznew,q,
from which the predicted probability Pˆ (Y = 1|znew,1, . . . , znew,q) is derived as Pˆ (Y =
1|znew,1, . . . , znew,q) = exp(ηˆnew)1+exp(ηˆnew) . In our two-stage approach, the estimated logistic
regression coefficients βˆ0, . . . , βˆq of the clinical covariates which are fitted in the first
step are passed to the second step that uses the corresponding linear predictor as an
offset.
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2.2 Boosting with component linear least squares
2.2.1 General algorithm
In this section, we give a short general overview of boosting as reviewed by Bu¨hlmann
and Hothorn [14], and explain which variant of boosting we use in the second step
of our two-stage procedure. The considered predictors are the molecular covari-
ates X1, . . . , Xp. The AdaBoost algorithm was originally developed by Freund and
Schapire as a machine learning tool, see [15] for an early reference. Friedman, Hastie
and Tibshirani [16] then developed a more general statistical framework which yields
a direct interpretation of boosting as a method for function estimation. The goal is to
estimate a real-valued function
f ∗(·) = argmin
f(·)
E[ρ(Y, f(X1, . . . , Xp))],
where ρ(·) is a loss function which will be discussed in this section. Friedman, Hastie
and Tibshirani [16] formulate boosting as a functional gradient descent algorithm for
estimating f(·) as sketched below [14].
1. Initialize fˆ [0](·) with an offset value, for instance fˆ [0](·) = 0 or fˆ [0](·) =
argminc n
−1∑n
i=1 ρ(yi, c). Set m = 0.
2. Increase m by 1. Compute the negative gradient − ∂
∂f
ρ(Y, f) and evaluate it at
fˆ [m−1](xi), for each observation i = 1, . . . , n:
ui = − ∂
∂f
ρ(yi, f)|f=fˆ [m−1](xi).
3. Fit the u1, . . . , un to x1, . . . ,xn using a so-called base procedure (which will be
discussed later in this section):
(xi, ui)
n
i=1
base procedure
−→ gˆ
[m](·).
4. Update fˆ [m](·) = fˆ [m−1](·) + ν · gˆ[m](·), where 0 < µ ≤ 1 is a step-length factor
(see below), that is, proceed along an estimate of the negative gradient vector.
5. Iterate steps 2 to 4 until m = mstop for some stopping iteration mstop.
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2.2.2 The boosting version used in the present study
In the context of binary class prediction (i.e. when Y is binary), it is usual to use the
so-called log-likelihood loss function
ρlog-lik(y, f) = log2(1 + exp(−2yf))
in step 2 [14]. In the present study, we stick to this standard choice which yields
nice properties. For instance, it can be shown that the population minimizer of this
loss function has the intuitive form f ∗(X1, . . . , Xp) = 12 log
p(X1,...,Xp)
1−p(X1,...,Xp) , where
p(X1, . . . , Xp) = P (Y = 1|X1, . . . , Xp).
In order to fit a model which is linear in the molecular variables, componentwise
linear least squares regression is applied as an efficient base procedure in step 3. This
base procedure is defined as
gˆ(X1, . . . , Xp) = βˆj∗Xj∗ ,
where βˆj simply denotes the least square estimate of the coefficient βj in the univariate
regression model including Xj as single predictor
βˆj =
(
n∑
i=1
xijui
)
/
(
n∑
i=1
x2ij
)
,
and j∗ corresponds to the predictor yielding the best prediction in this univariate re-
gression model:
j∗ = arg min
1≤j≤p
n∑
i=1
(ui − βˆjxij)2.
Meanwhile, componentwise linear least squares can be considered as one of the stan-
dard base procedures for boosting. We choose it as a base procedure for the second
step of our two-stage analysis scheme. A major advantage of componentwise linear
least squares as a base procedure in the context of our two-stage approach is that the
final estimated function fˆ (mstop)(·) can be seen as a linear combination of the molecular
predictors X1, . . . , Xp of the same form as the linear combination of the clinical co-
variates Z1, . . . , Zq output by the first step. Hence, it is easy to combine both steps of
the analysis, as explained in Section 2.3.
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2.3 Combining logistic regression (step 1) and boosting (step 2)
In this section, we show how logistic regression and boosting as described in the
two above sections can be combined into a two-step procedure. We first present the
procedure for the case when the model with clinical covariates has to be estimated
from the data and then address the other scenario (application of a fixed risk score
known from a previous study).
Step 1
1.1 Fit a logistic regression model as outlined in Section 2.1 to the clinical covari-
ates Z1, . . . , Zq, yielding estimates βˆ0, βˆ1, . . . , βˆq for the logistic regression co-
efficients.
1.2 Compute the linear predictor ηˆ(1)i = βˆ0 + βˆ1zi1 + · · ·+ βˆqziq for i = 1, . . . , n.
Step 2: Boosting regression
This step involves one method parameter, the number of boosting iterations mstop,
which is discussed in Section 2.5.
2.1 Define the offset function fˆ [0](·) as fˆ [0](zi1, . . . , zip) = ηˆ(1)i and run the boosting
algorithm given in Section 2.2 using the log-likelihood loss function ρlog-lik and
componentwise linear least squares as a base procedure with mstop boosting iter-
ations, as implemented in the R package mboost [17, 18]. Derive the estimates
βˆ∗0 , βˆ
∗
1 , . . . , βˆ
∗
p for the intercept and the regression coefficients of the variables
X1, . . . , Xp. Note that, in practice, many of these coefficients are zero.
2.2 Compute the resulting linear predictor as
ηˆ
(2)
i = βˆ0 + βˆ1zi1 + · · ·+ βˆqziq + βˆ∗0 + βˆ∗1xi1 + · · ·+ βˆ∗pxip.
2.3 Compute the predicted probabilities pˆ(2)i from the linear predictor as pˆ
(2)
i =
exp(ηˆ
(2)
i )
1+exp(ηˆ
(2)
i )
and derive the average negative binomial log-likelihood as
` =
1
n
n∑
i=1
(
(0.5 + 0.5yi) log(pˆ
(2)
i ) + (0.5− 0.5yi) log(1− pˆ(2)i )
)
.
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A small negative binomial log-likelihood indicates good model fit. Note that we could
have used another goodness criterion in place of the negative binomial log-likelihood.
However, the binomial log-likelihood is especially appropriate, since it is the crite-
rion optimized by the boosting procedure. To assess the additional predictive value of
the molecular data, we suggest to compare ` to the negative binomial log-likelihood
obtained from permuted data, as outlined in Section 2.4.
In the situation where a risk score is already available (e.g. from a previous publica-
tion), step 1 can be skipped. The linear predictor corresponding to the risk score is used
as an offset in boosting regression in place of the estimated linear predictor ηˆ(1)i . In the
case where the risk score is given in form of the event probability P (Y = 1) = p(RS)i
for each observation, we first have to convert the probabilities into linear predictors:
η
(RS)
i = log
p
(RS)
i
1− p(RS)i
.
This linear predictor is then used as an offset in boosting regression in place of the esti-
mated linear predictor ηˆ(1)i . Our method can thus be accommodated to situations where
the clinical risk score is not based on a linear predictor in the context of logistic regres-
sion (for instance a risk score corresponding to a classification tree). Alternatively, our
method can also be used to globally assess the molecular variables independently of
any clinical covariates. This would be done by ignoring the first step (logistic regres-
sion) of our method and simply setting the offset to the value of the intercept.
2.4 Permutation-based testing procedure
We consider the null-hypothesis that the variables X1, . . . , Xp have no additional pre-
dictive power given the clinical covariates. The considered model is given as
log
P (Y = 1)
P (Y = −1) = β0 +
q∑
j=1
βjZj +
p∑
j=1
β∗jXj
and the null-hypothesis is formally stated as
H0 : β
∗
1 = · · · = β∗p = 0.
We suggest to test this null-hypothesis using a permutation procedure by permuting
X1, . . . , Xp only. More precisely, we replace x1, . . . ,xn by xσ(1), . . . ,xσ(n), where
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σ is a random permutation of (1, . . . , n), while the clinical covariates zi are not per-
muted. The two-step procedure is applied and the negative binomial log-likelihood ` is
computed again for this permuted data set. The whole procedure is repeated a number
of timesB, yielding the negative binomial log-likelihoods `1, . . . , `B. The permutation
p-value is then obtained as
p-value =
1
B
B∑
b=1
1(`b ≤ `),
where 1 denotes the indicator function.
2.5 The choice ofmstop
When boosting is used for building a prediction model, the choice of the number of
boosting iterations is crucial. A too large mstop would yield an overcomplex model
overfitting the training data, while a too small mstop would yield a too sparse model
that do not fully exploit the available predicting information. In practice, the number
of boosting iterations can be selected using an AIC-like criterion or by minimization
of the out-of-sample negative binomial likelihood within a bootstrap procedure [14].
In contrast to what happens in the context of prediction, the results of our ap-
proach for the assessment of additional predictive value are not strongly affected by
the number of boosting iterations. To illustrate this, we follow the simulation scheme
described in the Results section and consider two extrem case: a) one strongly infor-
mative molecular variable (µX = 5, p∗ = 1) and b) 200 very weakly informative
molecular variables (µX = 0.2, p∗ = 200), all the other molecular variables and clin-
ical covariates being irrelevant for the prediction problem. The second setting can be
considered as an extreme case, since there are often less than 200 informative variables
in practice, and relevant between-group shifts are often larger than µX = 0.2. In these
settings, we compute the negative binomial log-likelihood ` as well as its permuted
versions `1, . . . , `B for a grid of mstop values ranging from 10 to 2000. The resulting
curves are displayed in Figure 1. Similar curves are obtained for different values of the
simulation parameters.
To sum up, the curve of the original data set (with informative X variables) de-
creases with increasing mstop more rapidly than the curves of the permuted data sets
until a certain value of mstop. After this value, all curves are approximately parallel.
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Hence, further increasing mstop would not change the test result. This is because,
roughly speaking, the newly added components do not improve the model anymore
- even with the original non-permuted variables. Except from the computational ex-
pense, there is no inconvenience to choose a relatively large mstop, and a large mstop
may better detect weak effects. In our experience, mstop = 1000 is a good compromise
between computation time and the capacity to detect weak effects.
3 Results
3.1 Simulation design
In all settings, the number n of observations is set to n = 100, the number p of molecu-
lar predictors to p = 1000 and the number q of clinical predictors to q = 5. The binary
variable Y is drawn from a Bernoulli distribution with probability of success 0.5. The
relevant molecular variables follow the conditional distributionXj|Y = 1 ∼ N (µX , 1)
and Xj|Y = −1 ∼ N (0, 1), for j = 1, . . . , p∗. The other molecular variables
Xp∗+1, . . . , Xp simply follow a standard normal distribution. Similarly, the clinical
covariates are drawn from the conditional normal distribution Zj|Y = 1 ∼ N (µZ , 1)
and Zj|Y = −1 ∼ N (0, 1), for j = 1, . . . , q.
We first consider the case of non-informative clinical covariates (µZ = 0) and
uncorrelated variables X1, . . . , Xp, Z1, . . . , Zq, and consider the six following cases:
(null) p∗ = 0 (no informative molecular variables), for comparison
(a) p∗ = 5 and µX = 0.5: few relevant variables, weak between-group shift
(b) p∗ = 5 and µX = 0.8: few relevant variables, strong between-group shift
(c) p∗ = 50 and µX = 0.3: many relevant variables, very weak between-group shift
(d) p∗ = 50 and µX = 0.5: many relevant variables, weak between-group shift
(e) p∗ = 200 and µX = 0.3: very many relevant variables, very weak between-group
shift
To show that our method focuses on the additional predictive value of high-
dimensional data, we also consider the following special setting (f): both the q = 5
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clinical covariates and the p∗ = 5 relevant molecular predictors are highly predictive
(µZ = µX = 1), but in the first case they are mutually uncorrelated (f.1), while we
have X1 = Z1, . . . , X5 = Z5 in the second case (f.2).
For each setting, 100 simulated data sets are generated. The two following methods
are applied to each data set for each setting:
A. Our method with mstop = 100, 500, 1000 and B = 200 permutation iterations
B. Goeman’s global test [7] with adjustment for the clinical covariates using the
globaltest package [9]
3.2 Simulation results
Figure 2 represents boxplots of the p-values for the eight different settings. Three im-
portant results can be observed from the boxplots. Firstly, the influence of the parame-
ter mstop seems to be minimal in all settings except in setting (f.1), where mstop = 1000
has a noticeably better power. Hence, this simulation study confirms that, as outlined
in Section 2.5, the choice of mstop is not of crucial importance in most cases, and that
mstop should rather be large. Secondly, our method shows high power in very different
difficult situations such as a small number of strong predictors or a large number of
very weak predictors. In all the examined settings, its power was better than the power
of the global test. The power difference between our approach and the global test is
especially striking in the case of a small number of strong predictors (b). Another in-
teresting result is that the p-values of the global test are not uniformly distributed in
the null case. Thirdly, our method finds additional predictive value in setting (f.1) but
does not in setting (f.2) (i.e. when X1 = Z1, . . . , Xq = Zq), thus fulfilling requirement
1.
3.3 Real data analysis
We first analyze the ALL data set included in the Bioconductor package ALL [19].
The ALL data set is an expression set from a study on T- and B-cell acute lymphoblas-
tic leukemia including 128 patients using the Affymetrix hgu95av2 chip with 12,625
probesets [20]. The data has been preprocessed using RMA. We consider the response
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remission/no remission, and the clinical covariates age, sex, T- vs. B-cell. After remov-
ing patients with missing values in the response or in the clinical covariates, we obtain
a data set with 97 patients with remission and 15 patients without remission.
The second example data set considered in this paper is the Van’t Veer breast cancer
data set [21]. The data set prepared as described in the original manuscript (only genes
that show 2-fold differential expression and p-value for a gene being expressed < 0.01
in more than 5 samples are retained, yielding 4348 genes) is included in the R package
DENMARKLAB [22], which we use in the article. The available clinical variables
are age (metric), tumor grade (ordinal), estrogen receptor status (binary), progesterone
receptor status (binary), tumor size (metric) and angioinvasion (binary).
We apply the global test with adjustment for the clinical covariates and our new ap-
proach (with mstop = 100, 500, 1000) to both data sets. Additionally, we also apply the
global test without adjustment and our method without first step (i.e. without adjust-
ment for clinical covariates) for comparison. The results are given in Table 1. Whereas
the ALL gene expression data seem to have additional predictive value, the Vant’Veer
data do not, which corroborates previous findings [2, 10]. A noticeable result of both
Goeman’s global test and our new approach is that the ALL data have more predic-
tive value with adjustment than without adjustment, which may indicate that clinical
and gene expression data are correlated and have contradictory effects on the response
variable. In contrast, the Vant’Veer gene expression data seem to be marginally infor-
mative, but their predictive value vanishes when adjustment is performed.
3.4 Good practice declaration
Our simulation and real data studies was performed with the values mstop =
100, 500, 1000 only. These values were chosen based on preliminary analyses in the
vein of Section 2.5, but not based on the final results. The simulation settings were
chosen based on short preliminary studies. The aim of these preliminary studies was to
ensure informativeness in the sense that we avoided settings where all hypotheses are
rejected (too strong predictors) or all hypotheses are accepted (too weak predictors).
The aim of the preliminary study was not to select the settings that would advantage
our method compared to the concurrent globaltest approach. For reproducibility, the
codes implementing our procedure and the simulation and real data studies are avail-
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able as supplementary files.
4 Conclusions
We propose a simple boosting-based permutation procedure for testing the additional
predictive value of high-dimensional data. Our approach shows good power in very
different situations, even when a very small proportion of predictors are informative
or when the signal in each informative predictors is very weak. Unlike approaches like
pre-validation [23], it assesses the additional predictive value of high-dimensional data
in the sense that the clinical covariates are involved in the model as a fixed offset.
We provide clear advice for choosing the parameters involved in the procedure. The
shrinkage factor ν should be set to the standard default value ν = 0.1 as recommended
in previous publications [14]. The number B of permutations should be set as high
as computationally feasible (the higher B, the more precise the p-value). The most
delicate parameter is the number of boosting iterations mstop. Note, however, that the
choice of mstop is not as crucial as in the context of prediction and almost no influence
on the results. Except for the computational expense, there is almost no inconvenience
to set mstop to a very large value. In practice, the value mstop = 1000 seems to be
reasonable. On one hand, the log-likelihood curves of real and permuted data plotted
against m are approximately parallel and usually do not intersect even if the optimal
number of boosting steps is much smaller. On the other hand, mstop = 1000 allows to
detect very weak signals at the border of biological relevance. In a way, our method
circumvents the difficult problem of complexity selection with high-dimensional data.
Note that our methodology can be easily generalized to a wide range of more com-
plex regression problems such as survival analysis or non-linear regression. These
problems can all be handled within the boosting regression framework using the
mboost package [17, 18]. Hence, our approach is essentially not limited to linear ef-
fects, although we focus on this special case in the present paper. Since, especially
for linear models, an efficient implementation of boosting is available [17], the com-
putational effort of our procedure is manageble with standard hardware. Furthermore,
the permutation procedure can be run in parallel which further reduces the required
computing time [24].
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Figures
Figure 1 - Choice ofmstop
Negative log-likelihood for the original data (red) and the permuted data (black)
against the number of iterations mstop. (a) µX = 5, p∗ = 1. (b) µX = 0.2, p∗ = 200.
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Figure 2 - Boxplots of p-values
Boxplots of the p-values for the eight settings described in Section 3.1 using our new
method with mstop = 100, 500, 1000 (gray boxes) and using Goeman’s global test
(white boxes).
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Tables
Table 1
global test boosting-based permutation test
adjustment mstop = 100 mstop = 500 mstop = 1000
ALL yes 0.039 0.020 0.041 0.048
no 0.078 0.013 0.071 0.127
Van’t Veer yes 0.114 0.507 0.288 0.216
no 0.015 0.004 0.006 0.005
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